Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Vertex Pharmaceuticals and Affinia Therapeutics have formed a pact to research engineered adeno-associated virus capsids for delivering gene therapies. Affinia will get $80 million in up-front and research payments to create capsids that deliver Duchenne muscular dystrophy, myotonic dystrophy type 1, and cystic fibrosis treatments. Affinia launched in March with $60 million in series A financing. It’s based on technology developed at the Grousbeck Gene Therapy Center.
This article has been sent to the following recipient: